Hopes for Medicare reforms persist in Congress
This article was originally published in Clinica
With prospects for a prescription drug benefit now in congressional limbo, a provider "give-back" bill looks like the most likely vehicle for the device industry to advance its list of potential Medicare reforms through Congress this year.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.